Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · IEX Real-Time Price · USD
-0.16 (-2.27%)
At close: Aug 12, 2022 4:00 PM
-0.23 (-3.34%)
After-hours: Aug 12, 2022 7:59 PM EDT

Company Description

Virax Biolabs Group is a holding company incorporated with no material operations of its own.

We conduct our substantial operations in the United Kingdom and Hong Kong with operating subsidiaries in Singapore, China and British Virgin Islands and have been operating since 2013.

We are a global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and med-tech and Personal Protective Equipment products for the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology.

Our mission is to minimize the risks of viruses throughout the world via our products offerings. Our product portfolio includes: (i) diagnostics test kits sold through our “ViraxClear” brand; (ii) med-tech and PPE products sold through our “ViraxCare” brand; and (iii) sourced brands of third party suppliers, independent of our own brands.

We also expect to launch an upcoming brand “Virax Immune”, with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral diseases.

Virax Biolabs Group Limited
Country United Kingdom
Founded 2013
IPO Date Jul 21, 2022
Industry Biotechnology
Sector Health Care
Employees 6
CEO James Foster

Contact Details

30 Broadwick Street
London W1F 8LX
United Kingdom
Phone 44 20 7788 7414

Stock Details

Ticker Symbol VRAX
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency US Dollars
IPO Price $5.00
CIK Code 1885827
SIC Code 2835

Key Executives

Name Position
James Foster Chairman and Chief Executive Officer
Jason D. Davis Chief Financial Officer
Cameron Lee Shaw Chief Operating Officer and Director
Mark James Ternouth Chief Technical Officer
Dr. Tomasz Evan George Chief Scientific Officer